Annovis Bio, Inc. (FRA:07X)

Market Cap	55.79M -5.0%
Revenue (ttm)	n/a
Net Income	-21.21M
EPS	-1.23
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	598
Open	2.025
Previous Close	2.040
Day's Range	2.025 - 2.025
52-Week Range	1.050 - 4.610
Beta	n/a
RSI	36.98
Earnings Date	Mar 27, 2026

About Annovis Bio

Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company’s lead product candidate is Buntanetap, which is in phase 2/3 to treat alzheimer’s disease, as well as in phase 3 to treat parkinson’s disease; and is in phase 2 clinical trial to treat lewy body dementia. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial to treat later stages of alzhei...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2008
• Employees: 12
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 07X

Financial Performance

Financial numbers in USD